Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Mechanism Discovered for Cancer Cell Metastasis

By BiotechDaily International staff writers
Posted on 18 Jul 2012
Image: Electron microscopy of a tumor cell (blue, green) on the way to extravasate through an alveolar endothelium blood capillary (purple, red). Tumor cell protrusions are seen forming their way through the endothelial cell (Photo courtesy of the University of Zurich.)
Image: Electron microscopy of a tumor cell (blue, green) on the way to extravasate through an alveolar endothelium blood capillary (purple, red). Tumor cell protrusions are seen forming their way through the endothelial cell (Photo courtesy of the University of Zurich.)
Image: Tumor cells (green) adhere on the endothelium (red) that becomes activated and permeable via CCL2-CCR2 signaling. Tumor cell extravasation is facilitated by recruited monocytic cells (blue). Technique: Adaptation of confocal image stacks creating an artificial surface. (Photo courtesy of the University of Zurich.)
Image: Tumor cells (green) adhere on the endothelium (red) that becomes activated and permeable via CCL2-CCR2 signaling. Tumor cell extravasation is facilitated by recruited monocytic cells (blue). Technique: Adaptation of confocal image stacks creating an artificial surface. (Photo courtesy of the University of Zurich.)
Scientists have for the first time discovered a mechanism by which cancer cells metastasize to other parts of the body, where they form the secondary tumors responsible for the vast majority of cancer-related deaths.

Until now, molecular level processes leading to the metastatic spread into certain organs have been unknown, it being unclear as to how the secondary cells are able to leave the bloodstream and enter the tissue of other organs. A European team of physiologists and neuropathologists, primarily through the University of Zurich (Switzerland), have now identified a biochemical pathway underlying the origin of metastasis formation whereby at least some, if not all, types of cancer cells metastasize out of the bloodstream. The team, led by principal investigators Dr. Lubor Borsig and Dr. Mathias Heikenwalder, demonstrated that intestinal cancer cells manipulate specific “doorman receptors” on the endothelium of the blood vessels.

Elevated levels of the chemokine CCL2 are known to be characteristic of metastasizing breast, prostate, and intestinal bowel types of cancer cells; clinically, high CCL2 values have been primarily taken as an indication of strong tumor growth and a poor prognosis. Increased CCL2 expression has also been correlated with recruitment of CCR2+Ly6Chi monocytes, CCR2 being a CCL2-activated receptor. Based on in vivo and in vitro experiments, the current study has now shown CCL2 to be far more than an indicator of the cancer’s aggressiveness – CCL2 was found to be part of a signal transduction mechanism critical in helping at least some types of cancer cells metastasize.

The study describes CCL2 upregulation in metastatic UICC stage IV colon carcinomas and demonstrates that tumor cell-derived CCL2 activates the CCR2+ endothelium and thereby leads to increased vascular permeability in vivo. CCR2 acts as a “doorman receptor” activated by CCL2. The role of the CCR2 doorman in a healthy organism is not known and has only now been detected on the endothelium for the first time. Dr. Borsig suspects that the doorman is involved in modulating the permeability of the blood vessels during the body’s immune response.

“The mechanism discovered will yield a completely new approach for the development of drugs to combat metastasis in breast, prostate, and bowel cancer,” Dr. Borsig is convinced. Suppressing the tumor’s chemokine expression or blocking the doorman specifically for the tumor chemokine to inhibit cancer cells from entering healthy tissue from the bloodstream is conceivable. “If we can succeed in preventing the cancer cells from leaving the bloodstream, the metastasis can be fought directly at the source,” concludes Dr. Borsig.

Related Links:

University of Zurich






Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.